FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation’s Investigational Drug to Treat Diabetes

[GlobeNewswire] – VALENCIA, Calif. — MannKind Corporation today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA(R) … more

View todays social media effects on MNKD

View the latest stocks trending across Twitter. Click to view dashboard

See who MannKind is hiring next, click here to view